Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

被引：14
|
作者：
Meunier, Benoit [2 ]
Rico, Audrey [1 ]
Seguier, Julie [2 ]
Boutiere, Clemence [1 ]
Ebbo, Mikael [2 ]
Harle, Jean Robert [2 ]
Schleinitz, Nicolas [2 ]
Pelletier, Jean [1 ]
机构：
[1] Hop La Timone, AP HM, Pole Neurosci Clin, Serv Neurol, F-13385 Marseille, France
[2] Hop La Timone, AP HM, Dept Med Interne, Marseille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 06期
关键词：
Multiple sclerosis; alemtuzumab; hemolytic anemia; CONTROLLED PHASE-3 TRIAL;
D O I：
10.1177/1352458517729766
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.
引用
收藏
页码：811 / 813
页数：3
相关论文
共 50 条
  • [31] A CASE OF WARM AUTOIMMUNE HEMOLYTIC ANEMIA
    Sherwani, N.
    Roubique, B.
    Jaber, V. R.
    DiMasi, T.
    Engel, L. S.
    Walvekar, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (02) : 562 - 562
  • [32] Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab
    Carlson, Aaron
    Bozinov, Nina
    Kipp, Lucas
    Dunn, Jeffrey
    Lock, Christopher
    NEUROLOGY, 2018, 90
  • [33] Sarcoidosis following alemtuzumab treatment for multiple sclerosis
    Willis, Mark D.
    Hope-Gill, Ben
    Flood-Page, Patrick
    Joseph, Fady
    Needham, Ed
    Jones, Joanne
    Coles, Alasdair
    Robertson, Neil P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) : 1779 - 1782
  • [34] Life-Threatening Hemolytic Anemia after Intrapleural Instillation of OK-432 for Treatment of Congenital Chylothorax
    Sze, Steve W. P.
    Ng, Pak C.
    Lam, Hugh S.
    NEONATOLOGY, 2016, 110 (04) : 303 - 306
  • [35] Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis
    Costelloe, Lisa
    Jones, Joanne
    Coles, Alastair
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (03) : 335 - 341
  • [36] Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab
    McAlister, Renee K.
    Talbott, Mahsa S.
    Reddy, Nishitha M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 706 - 709
  • [37] Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia
    Rovelli, Attilio
    Corti, Paola
    Beretta, Chiara
    Bovo, Giorgio
    Conter, Valentino
    Mieli-Vergani, Gorgina
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 45 (05): : 596 - 599
  • [38] Melanoma following treatment with alemtuzumab for multiple sclerosis
    Pace, A. A.
    Zajicek, J. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : E70 - E71
  • [39] Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
    Phelps, Richard
    Winston, Jonathan A.
    Wynn, Daniel
    Habek, Mario
    Hartung, Hans-Peter
    Havrdova, Eva Kubala
    Markowitz, Glen S.
    Margolin, David H.
    Rodriguez, Claudio E.
    Baker, Darren P.
    Coles, Alasdair J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (09) : 1273 - 1288
  • [40] SARCOIDOSIS FOLLOWING ALEMTUZUMAB TREATMENT FOR MULTIPLE SCLEROSIS
    Willis, M. D.
    May, K.
    Hope-Gill, B.
    Flood-Page, P.
    Jeffrey, D.
    Joseph, F.
    Robertson, N. P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A54 - A55
12345